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A subset of individuals infected with human immunodeficiency virus 1 (HIV-1) develops broadly 
neutralizing antibodies (bNAbs) that can prevent infection, but it has not yet been possible to elicit 
these antibodies by immunization. To systematically explore how immunization might be tailored 
to produce them, we generated mice expressing a diverse repertoire of light chains and predicted 
germline or mature heavy chains of a potent bNAb to the CD4 binding site (CD4bs) on the HIV-1 
envelope glycoprotein (Env). Immunogens specifically designed to activate B cells bearing 
germline antibodies are required to initiate immune responses, but they do not elicit bNAbs. In 
contrast, native-like Env trimers fail to activate B cells expressing germline antibodies but elicit 
bNAbs by selecting for a restricted group of light chains bearing specific somatic mutations that 
enhance neutralizing activity. The data suggest that vaccination to elicit anti-HIV-1 antibodies will 
require immunization with a succession of related immunogens.
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Introduction
A fraction of HIV-1 infected individuals develop potent bNAbs that target several 
independent sites on gp160, the viral envelope glycoprotein (Env) (West et al., 2014). When 
passively transferred into non-human primates or into genetically engineered or humanized 
mice, these antibodies can protect against challenge with chimeric simian/human 
immunodeficiency virus (SHIV) or HIV-1 viruses, respectively (Burton et al., 2012; Klein et 
al., 2013; Mascola and Haynes, 2013; West et al., 2014). Antibodies were also the only 
correlate of protection in a recent phase 3 human HIV-1 vaccine trial that showed limited 
efficacy (Karasavvas et al., 2012; Rerks-Ngarm et al., 2009). Thus, one of the goals of the 
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HIV-1 vaccine effort has been to elicit bNAbs by immunization. However, this goal has not 
been achieved despite over 25 years of concerted vaccination efforts.
Why it is so difficult to elicit these antibodies was only fully appreciated after the advent of 
single cell antibody cloning techniques (Klein et al., 2013; West et al., 2014). Antibody 
cloning revealed that anti-HIV-1 antibodies are unusual in that they carry large numbers of 
somatic hypermutations that are required for binding to most recombinant HIV-1 Env 
antigens and for broad neutralization (Mouquet et al., 2010; Scheid et al., 2011; Wu et al., 
2010). These mutations are likely to arise as a result of multiple rounds of hypermutation 
and selection in the germinal center in response to rapidly evolving escape mutations in the 
HIV-1 Env (Mouquet et al., 2010; Scheid et al., 2009). This idea is supported by the 
observation that bNAbs co-evolve with HIV-1 in the host through multiple rounds of HIV-1 
escape from antibody pressure (Doria-Rose et al., 2014; Klein et al., 2013; Liao et al., 2013; 
Wu et al., 2015). Considered together, these findings have led to the hypothesis that eliciting 
such antibodies may require using a series of engineered or naturally arising antigens to 
direct the antibody response (Dimitrov, 2010; Doria-Rose et al., 2014; Jardine et al., 2013; 
Klein et al., 2013; Liao et al., 2013; Wu et al., 2011). According to this idea, an antigen that 
activates B cells carrying a germline antibody would initially be used to expand a reactive B 
cell clone and produce a group of somatic variants by hypermutation. To shepherd the 
antibody response towards broad neutralization, the initial immunization would be followed 
by one or a series of related antigens.
To test this hypothesis, we produced Ig heavy chain knock-in mice expressing the predicted 
germline (GLVH) or mature mutated (MuVH) version of 3BNC60, a bNAb that targets the 
CD4 binding site (CD4bs) of HIV-1 (Scheid et al., 2011). 3BNC60 is one of a closely 
related group of potent antibodies referred to as VRC01-class antibodies (West et al., 2012), 
arising in several different individuals, all of which are derived from IgHV1-2*02 (West et 
al., 2014). In addition to the shared origin of their heavy chains, this group of antibodies all 
carry light chains that have short (5 amino acid) third complementarity determining regions 
(CDR3s) (West et al., 2012; Zhou et al., 2013).
Mice that carry heavy chain knock-in genes have a restricted B cell repertoire because the 
heavy chain is fixed. Nevertheless, the repertoire remains relatively diverse because the 
antibody light chain is produced by random VJ recombination in developing B cells. Thus, 
only a small fraction of the B cells carry heavy and light chains that combine to produce 
antibodies able to bind to the HIV-1 Env (see below). Immunization of GLVH mice affords 
the opportunity to evaluate antigens for their ability to select B cells expressing light chains 
that show features that could support bNAb evolution. In contrast, MuVH mice represent a 
synthetic intermediate since the human heavy chain carries all of the required mutations, but 
the mouse light chain is germline.
To track the evolution of the HIV-1 antibody response in GLVH and MuVH mice, we 
immunized them with antigens designed to bind to the predicted unmutated precursor of 
3BNC60, or with BG505 SOSIP trimers that resemble the native HIV-1 Env.
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Results
3BNC60 knock-in mice
GLVH and MuVH mice were produced by gene targeting using C57Bl-6 embryonic stem 
cells (Pelanda et al., 1997; Shih et al., 2002) (Figure S1A). GLVH reverts all of the heavy 
chain residues outside of CDRH3 (Hoot et al., 2013). CDRH3 cannot be reverted with 
certainty because the sequence represents the combined effects of random V(D)J 
recombination, N addition, deletion and somatic mutation. Both strains showed near normal 
frequencies of immature and recirculating B cells in the BM (Figure S1B) and of mature B 
cell populations in spleen (Figure S1C).
To determine the frequency of naive B cells that bind to Env-based antigens in the knock-in 
mice, we stained splenocytes with an improved version (eOD-GT8) of the previously 
described immunogen eOD-GT6, an engineered outer domain of gp120 designed to bind to 
both germline and mature versions of 3BNC60 and other VRC01-class antibodies (see 
below and (Jardine et al., 2013)). The average number of naive B cells that bind to eOD-
GT8 in GLVH and MuVH mice (0.08% and 0.13%, respectively) was similar to that found in 
wild type C57Bl6 mice (0.05%) indicating that these cells are rare and found at frequencies 
similar to those in wild type C57Bl6 mice (Figure 1A–B). To examine the antibody 
repertoire in naive B cells in these mice we isolated single cells by flow cytometry and 
sequenced their Ig genes. As expected, the heavy chain was always the product of the 
respective knock-in allele and the mouse light chain sequences were less diverse than in 
wild type C57Bl6 B cells (51/59, 24/44 and 33/63 unique sequences for wild type C57Bl6, 
GLVH and MuVH respectively) (Figure 1C). Consistent with the rare occurrence of antigen-
binding cells in the naive knock-in mice (Figure 1A and B), none of the mouse light chains 
showed the 5-residue CDRL3 signature typical of authentic 3BNC60 or of other VRC01-
class antibodies (Figure 1D).
Immune responses in 3BNC60 GLVH knock-in mice
Like most other potent bNAbs, reversion of the somatic mutations in the 3BNC60 antibody 
to the predicted germline antibody results in complete loss of affinity and neutralizing 
activity for all recombinant HIV-1 Env proteins and viruses tested (Hoot et al., 2013; Jardine 
et al., 2013; McGuire et al., 2013; Mouquet et al., 2010; Scheid et al., 2011; Xiao et al., 
2009) (Figure S2A and S2B). To determine whether naive GLVH B cells can be stimulated 
with antigens that are specifically engineered to activate cells expressing germline VRC01-
class antibodies (Figure S2C), we immunized these mice and wild type C57Bl6 controls 
with eOD-GT8 60mers or with multimerized 426c.TM4ΔV1-3 ((McGuire et al., 2014) and 
see methods). Immunization produced a robust antibody response in wild type C57Bl6 and 
GLVH mice after one or two immunizations (Figure 2A and B and Figure S3A and S3B). 
Although the response was not restricted to the CD4bs, as determined by ELISA, sera from 
the eOD-GT8 60mer-immunized mice showed some preference for the wild type vs. a 
control eOD-GT8 CD4bs knock-out protein (Figure 2A and Figure S3A). Finally, none of 
the sera from the eOD-GT8 60mer-immunized mice showed cross-reactivity to a native-like 
BG505 SOSIP (Julien et al., 2013; Sanders et al., 2013) or a YU2 gp140 foldon trimer (YU2 
gp140-F) (Yang et al., 2002) (Figure 2C and Figure S3C).
Dosenovic et al. Page 4
Cell. Author manuscript; available in PMC 2016 June 18.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
eOD-GT8-binding IgG+ B cells are rare in GLVH naive mice but increase to 5.8% on 
average after immunization (Figure S3D). A fraction of these cells appeared to express 
CD4bs-specific antibodies as measured by flow cytometry (Figure S3E). To further 
characterize the B cell responses to eOD-GT8 60mers in GLVH mice, we sorted single cells 
that bound to eOD-GT8, but not eOD-GT8 CD4bs knock-out, and cloned their antibody 
genes (Figure S3E). 71 light and 55 heavy chain sequences were obtained from 4 mice. As 
expected, all of the heavy chains were GLVH. The 71 antibodies include 8 clones ranging in 
size from 2–13 clonal members, one of which appeared in more than one mouse. In addition 
there were 13 cells that carried unique sequences (Figure 2D, Figure S3F and Table S1A). 
The CDRL3 lengths of the light chains showed a near normal distribution when compared to 
naive GLVH or control wild type C57Bl6 mice, with only one of the expanded clones 
showing the 5 residue CDRL3 signature typical of 3BNC60 and related antibodies (Figure 
2E, Figure S3G and Table S1A).
Out of 20 antibodies cloned from B cells expressing antibodies that bound to eOD-GT8 but 
not eOD-GT8 CD4bs knock-out by FACS, 7 were CD4bs specific as measured by ELISA 
(Figure 2F). However, none of the 17 monoclonal antibodies tested, neutralized any of the 
tier 1 and 2 viruses tested (Table S1B). We conclude that the eOD-GT8 60mer, an antigen 
designed to activate B cells expressing germline 3BNC60 antibody, and select only for early 
somatic mutations, elicits B cell responses in mice that carry germline knock-in antibody 
heavy chains including B cells expressing antibody light chains with 5-residue CDRL3s, but 
these antibodies do not neutralize HIV-1.
To determine whether GLVH B cells can respond to a more native appearing HIV-1 antigen 
in vivo, we immunized these mice and wild type C57Bl6 mice with BG505 SOSIP (Julien et 
al., 2013; Sanders et al., 2013) or YU2 SOSIP. Wild type C57Bl6 mice developed detectable 
antibody responses as measured by ELISA. In contrast, GLVH mice failed to respond to 
these antigens (Figure 2G and Figure S3H). We conclude that naive B cells expressing 
GLVH paired with a heterogenous group of mouse light chains fail to mount significant 
immune responses to BG505 SOSIP or YU2 SOSIP.
Immune responses in 3BNC60 MuVH knock-in mice
Serum from naive MuVH mice has no detectable HIV-1 Env-binding activity in ELISA or 
neutralizing activity in TZM-bl assays (Figure 3A–C and Figure S4A–B). To determine 
whether anti-HIV-1 antibodies can be elicited in these mice they were immunized three 
times, with eODGT8 60mers or BG505 SOSIP. The eOD-GT8 60mer immunization 
produced strong serologic responses in MuVH mice but the sera were not cross-reactive 
against other HIV-1 proteins such as 2cc-core (an engineered gp120 (Dey et al., 2009)) or 
YU2 gp140-F, and a fraction of the mice showed CD4bs specificity as measured by ELISA 
on eOD-GT8 and eOD-GT8 CD4bs knock-out (Figure 3A and Figure S4A). MuVH mice 
also developed strong serologic responses to BG505 SOSIP, but in contrast to eOD-GT8 
immunization, there was serologic cross-reactivity to 2cc core, as well as YU2 gp140-F. 
Moreover, a significant fraction of the response was CD4bs specific as determined by 
ELISA against YU2 gp140-F and a YU2 gp140-F CD4bs knock-out mutant protein (Figure 
3B and Figure S4B).
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To determine whether MuVH mice develop HIV-1 neutralizing responses we assayed mouse 
serum on a panel of 9 HIV-1 viruses (8 tier 2, and 1 tier 1) in TZMbl-assays (Li et al., 2005). 
We found that the eOD-GT8 60mer-immunized MuVH mice only showed modest levels of 
activity mainly against tier 2 Clade D (T247-23) and A (62357.14.D3.3489) viruses that lack 
glycosylation at position 276 (Genebank entry ACD63071 and ABY50658.1 respectively) 
(Figure 3C). In contrast, all seven out of ten BG505 SOSIP-immunized MuVH mice that 
showed a robust response to BG505 SOSIP in ELISA, developed strong neutralizing 
responses against the autologous Clade A virus. In addition, high levels of neutralization 
were also evident against T247-23, and 62357.14.D3.3489, and more modest levels of 
neutralization were seen against three other clade A tier 2 viruses. Finally, four of the seven 
also showed a low level of neutralizing activity against the clade B tier 2 strain YU2.DG 
(Figure 3C). Thus, BG505 SOSIP trimers elicit potent responses with some cross-clade 
breadth in MuVH mice but eOD-GT8 60mer does not.
eOD-GT8-binding IgG+ B cells cannot be detected in naive MuVH mice but increase to 15% 
and 30% after immunization with eOD-GT8 60mers or BG505 SOSIP, respectively (Figure 
S4C). Thus, both antigens were able to induce clonal expansion and antigen-specific 
memory B cells. To characterize the antibodies that develop in the MuVH mice, we isolated 
and cloned the antibodies from antigen-specific memory B cells (Figure S4D and S4E).
As expected, all of the heavy chains obtained carried the MuVH knock-in sequence. A total 
of 138 and 269 light chains were cloned from mice immunized with eOD-GT8 60mers and 
BG505 SOSIP respectively (Figure 4A, Table S2 and S4). The antibodies obtained from 
eOD-GT8 60mer-immunized mice represent 15 independent clones ranging in size from 2–
24 members, 4 of the clones appeared independently in both eOD-GT8 60mer-immunized 
mice. In addition there were 13 cells that carried unique sequences (Figure 4A and Table 
S2). In contrast to the antibodies obtained from eOD-GT8 60mer-immunized GLVH mice, 
the light chains from MuVH immunized mice were highly biased to express 5 aa-residue 
CDRL3s. Moreover, the fourth residue in the CDRL3 was highly selected for an E, which is 
an important residue in the 3BNC60 antibody and other VRC01 class antibodies. It forms a 
contact with the backbone of the V5 loop of HIV-1 Env (Scheid et al., 2011; Wu et al., 
2010; Zhou et al., 2013) (Figure 4A and B and Table S2). When assayed by ELISA, the 
majority of these antibodies were CD4bs specific to eOD-GT8, and a fraction was cross-
reactive to YU2 gp140-F (Figure 4C). However, despite CD4bs specificity, only two viruses 
(T247-2 and 62357.14.D3.3489, which lack glycosylation at amino acid position 276) were 
neutralized by the monoclonal antibodies tested (Fig 4D and Table S3). Thus, eOD-GT8 
60mer-immunization of MuVH mice is highly selective for a subset of mouse light chains 
with short CDRL3s that allow binding to the CD4bs of eOD-GT8, but this is not sufficient 
to produce broad neutralizing activity against tier 2 viruses.
Antibodies cloned from BG505 SOSIP-immunized MuVH mice were far more clonally 
restricted than those obtained after eOD-GT8 60mer immunization. Light chains were 
cloned from 269 cells from 3 separate mice, and again, in all cases analyzed the heavy chain 
was from the knock-in. In contrast to eOD-GT8 60mer, BG505 SOSIP-immunization was 
dominated by only six highly expanded clones, one of which arose independently in all three 
mice (Figure 4A and Table S4). Similar to eOD-GT8 60mer-immunization, the B cell clones 
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expanded by BG505 SOSIP-immunization were highly biased to express light chains with 5 
aa-residue CDRL3s that carry the E at the fourth position of CDRL3 (Figure 4A and B and 
Table S4) When tested by ELISA, all but 4 of the 20 antibodies elicited by BG505 SOSIP 
were CD4bs specific on eOD-GT8 and a fraction of these were cross-reactive to YU2 
gp140-F (Figure 4E). Finally, some of these monoclonal antibodies showed neutralizing 
activity against several tier 2 viruses (Figure 4D and Table S5). We conclude that in contrast 
to eOD-GT8−, BG505 SOSIP-immunization elicits neutralizing antibodies against a diverse 
group of tier 2 viruses in MuVH mice.
Somatic mutations
Only the antibodies arising from BG505 SOSIP-immunization neutralized tier 2 viruses with 
an intact glycosylation site at position 276 (Figure 4D, Table S3 and S5). To gain further 
insights into this phenomenon we analysed the monoclonal antibodies and somatic 
mutations that arose during the immunization.
The total number of light chain mutations arising as a result of immunization by the eOD-
GT8 60mer or BG505 SOSIP was similar in both strains of mice, irrespective of whether the 
knock-in heavy chain was germline or mature (Figure 5A). In addition, both immunogens 
selected for B cells bearing the same VL germline gene (VL10-94*01) carrying similar 
number of somatic mutations and nearly identical CDRL3s in MuVH mice (Figure 4A, 5B, 
Table S2 and S4). Thus, the nature of the immunogen did not influence the rate of somatic 
mutations in the light chains.
However, some mutations in VL10-94*01-expressing B cells appeared to be specifically 
selected by immunization with BG505 SOSIP because they were over-represented (Figure 
S5A). For example, Q90H was found in the 2nd position of CDRL3 of nearly all members of 
the VL10-94 clone obtained independently from three MuVH mice immunized with BG505 
SOSIP but rarely in the VL10-94 clone that arose after immunization with eOD-GT8 60mers 
(Figure 4A, Table S2 and S4, Figure S5A). While others such as the E mutation found in the 
4th residue of CDRL3 was selected by both immunogens (Figure 4A and Table S2 and S4). 
Thus immunization with BG505 SOSIP and eOD-GT8 60mers led to differential selection 
of somatically mutated light chains.
To determine whether light chain mutations might be responsible for increasing neutralizing 
activity after BG505 SOSIP immunization, we produced an antibody that carries the MuVH 
and the predicted germline light chain of VL10-94*01 (GL in Figure 5C, Table S3 and S5). 
When this antibody was compared to BG505 SOSIP-derived monoclonal antibodies (mAbs), 
the reverted antibody showed only modest activity. The reverted antibody was similar to the 
eOD-GT8 60mer-derived VL10-94*01 mAbs indicating that only BG505 SOSIP-
immunization selects for light chain somatic mutations that increase neutralizing antibody 
activity in MuVH mice (Figure 5C). Moreover, the Q90H found in the CDRL3 of nearly all 
VL10-94-expressing clones derived from BG505 SOSIP-immunized MuVH mice was 
sufficient to increase neutralizing activity (Figure 5C and D, Table S3 and S5). Additional 
mutations that further enhanced or interfered with neutralizing activity appeared randomly 
(Figure 5C). Finally, there was no evidence for selection of specific mutations in the heavy 
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chain in MuVH B cells as seen by the absence of significant clonal expansion of any 
particular mutation (Figure S5B).
In contrast to the light chains, mutations in the knock-in VDJH sequence were significantly 
higher in GLVH than in MuVH B cells (Figure 5E and Figure S5B) even when comparing 
Peyer’s Patch germinal center B cells in unimmunized mice that are not responding to 
injected antigens (Figure 5F). However, the mutation rate in the germline intron downstream 
of JH4, which is contiguous to the VDJH, was similar in the two mouse strains (Figure 5G). 
We conclude that the somatic mutation machinery is equally active in the two knock-in B 
cell types, but the highly mutated MuVH is less susceptible to mutation than its unmutated 
GLVH counterpart.
Discussion
Immunoglobulin knock-in mice such as GLVH and MuVH provide a unique opportunity to 
examine the effects of specific immunogens and trace the evolution of an anti-HIV-1 
antibody starting from predicted germline or from a synthetic intermediate composed of a 
mutated human heavy V region chain and a mouse germline light chain. The B cells in these 
mice show reduced repertoire diversity because the heavy chain is fixed, nevertheless the 
light chains are free to recombine randomly and the resulting B cell repertoire contains only 
very rare cells that bind to the HIV-1 immunogens tested.
Immunization revealed that B cells bearing predicted germline antibodies only responded to 
antigens specifically designed to bind to these antibodies, and not to more native appearing 
HIV-1 Env trimers. This result is consistent with the observation that the germline version of 
3BNC60 and related antibodies fail to bind to nearly all tested recombinant HIV-1 Env 
antigens and supports the idea that specifically designed antigens will be required to elicit B 
cells bearing these antibodies (Hoot et al., 2013; Jardine et al., 2013; McGuire et al., 2013). 
Nevertheless, it remains possible that a more diverse repertoire of light chains would include 
a rare pairing that might be triggered by the native like BG505 SOSIP trimer.
One of the objectives of immunization with a germline-targeting antigen is to expand and 
further diversify rare clones of B cells that can serve as precursors of bNAbs. For 3BNC60 
and related CD4bs antibodies this would require selection of B cells expressing antibodies 
with short CDRL3s and somatic hypermutation in germinal centers. Although rare in the 
pre-immune repertoire, GLVH B cells expressing antibodies with short CDRL3s were 
enriched after immunization with the eOD-GT8 60mer, providing proof of concept for 
selection of germline precursors of this class of antibodies by germline targeting antigens. In 
contrast both the engineered antigens and the native-like BG505 SOSIP trimers elicited 
antigen-specific B cell responses in mice bearing MuVH. However, only BG505 SOSIP 
produced a significant neutralizing response.
Both types of antigens selected rare MuVH B cells expressing light chains with short 
CDRL3s and both induced similar levels of somatic hypermutation. It would be interesting 
to determine whether these cells would also be selected when competing with a complete 
repertoire of B cells in a wild type mouse. Nevertheless, the responses to the immunogens 
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differed in two important ways each of which likely contributed to the eventual selection of 
tier 2 neutralizing antibodies to HIV-1 by the BG505 SOSIP trimer. First, the repertoire of 
light chains that was selected to undergo clonal expansion by the trimer was far more 
restricted than for the eOD-GT8 60mer. This restriction is likely to be related to the glycan 
at position 276 that enforces the relatively narrow geometry of the recessed CD4 binding 
pocket in the trimer (Julien et al., 2013; Kwong et al., 1998; Lyumkis et al., 2013). Under 
physiologic conditions this cavity accommodates the single terminal Ig-like domain in CD4. 
Significant alterations including somatic mutations, deletions, or insertions must be made for 
the bulkier paired heavy and light chain Ig domains in 3BNC60 and related antibodies to 
access the CD4bs (West et al., 2014). Many of these alterations are already present in the 
heavy chain of MuVH B cells, facilitating extensive contacts with gp120 (West et al., 2014). 
Nevertheless, the steric restrictions imposed by the glycan at 276 in BG505 SOSIP limit the 
number of different light chains that can be recruited into the immune response against the 
trimer. In contrast, eOD-GT8 was designed to be a more open structure that is missing the 
glycan at position 276 and can accommodate germline antibodies. It therefore recruits a 
more diverse but overlapping set of antibodies in mice bearing the MuVH, none of which 
has significant breadth against tier 2 viruses in TZM-bl assays.
The second difference between the two immunogens was in their ability to select for IgVL 
mutations that enhance breadth and potency. In particular the Q90H mutation in the CDRL3 
of the VL10-94 light chains that are selected in the BG505 SOSIP immunized mice may aid 
in rigidifying the light chain contacts to the CD4bs. Structural modeling of the VL10-94 
light chain indicates that the histidine side chain, unlike the glutamine side chain, can adopt 
a commonly observed, low energy conformation that also makes stabilizing interactions 
within the light chain (Figure S5C). The planar packing with Y91, the close proximity to the 
N276 glycan, a hydrogen bond with CDRL1 and a potential for interacting with a gp120-
bridging water molecule may help preconfigure the antibody for engagement of the CD4bs. 
The modeling and neutralization data indicate that the mutation could cause structural 
changes that influence binding to gp120 and may be necessary for the activity of the BG505 
SOSIP elicited antibodies (Figure S5C).
Although only a small number of the mutations are likely to be crucial for breadth and 
potency, achieving the right combination of amino acid substitutions by random 
mutagenesis is a low probability event. Finding that the mature, fully mutated 3BNC60 VH 
suffers fewer mutations after immunization than the predicted germline 3BNC60 despite 
equal rates of somatic mutation in the light chains and in the JH4 intron suggests that the 
sequence of the VH is an important determinant of its susceptibility to hypermutation. 
Consistent with this idea, the fully mutated 3BNC60 VH has many fewer AID target sites 
than the predicted germline VH(Betz et al., 1993; Longerich et al., 2006; Neuberger et al., 
1998). RGYW/WRCY are preferred targets for somatic hypermutation: 9 out of 12 RGYW 
and 7 out of 8 WRCY motifs found in GLVH sequence are missing in MuVH (Figure S5D).
HIV-1 and SHIV infection can be prevented by passive infusion of potent bNAbs into mice 
or macaques, but despite significant efforts, including large clinical trials, all attempts to 
elicit such antibodies in humans by immunization have failed to date (Klein et al., 2013; 
Mascola and Haynes, 2013; West et al., 2014) Antibody cloning experiments revealed that 
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these bNAbs differ from most other antibodies in that they are significantly more mutated, 
leading to the suggestion that eliciting them would require immunization with a sequential 
series of different antigens selected or designed to shepherd the antibody response through 
several successive rounds of mutation and selection in germinal centers (Klein et al., 2013; 
Mouquet et al., 2010; Scheid et al., 2009). Consistent with this notion, elegant studies of 
human HIV-1 infection show a correlation between HIV-1 viral evolution and the antibody 
response (Doria-Rose et al., 2014; Liao et al., 2013; Wu et al., 2015). Our experiments 
demonstrate that specific immunogens are required to target B cells at different stages of 
evolution of the anti-HIV-1 neutralizing response and lend support to the idea that 
vaccination for HIV-1 will require a strategy that involves sequential immunization with 
different antigens.
Experimental procedures
Mice and immunizations
Knock-in mice were produced by gene targeting using the human VDJH sequences of the 
mature and germline 3BNC60 heavy chain (Hoot et al., 2013). The targeting vector was 
designed with homologous regions flanking the endogenous J segments, which results in the 
deletion of the J segments and thereby minimizes rearrangement of the wild type locus 
(Pelanda et al., 1997; Shih et al., 2002). Mice were immunized once every two weeks with 
10 μg of protein in Alum Imject (Thermo Scientific). Serum was collected two weeks after 
each immunization. All experiments were performed according to the protocols approved by 
the IACUC at Rockefeller University.
Protein production
eOD-GT8 is an improved version of eOD-GT6 (Jardine et al., 2013). The eOD-GT8 CD4bs 
knock-out carries mutations to reintroduce the N276 glycan and also includes D368R and 
N279A. eOD-GT8 60-mers for immunization and monomers for ELISA detection were 
produced as previously described (Jardine et al., 2013). The 426c.TM4ΔV1-3 immunogen 
(+/− AviTag) is a derivative of the 426c.NLGS.TMΔV1-3 (McGuire et al., 2014) with the 
following additional modifications: D276N, S278R, G471S (HXB2 numbering). The protein 
was produced as previously described (McGuire et al., 2014). Multimerized 
426c.TM4ΔV1-3 was generated as follows; Avi-tagged and biotinylated 426c.TM4ΔV1-3 
was mixed with streptavidin and biotinylated dextran (Life Technologies) at a 3:1 ratio of 
Env to biotin, with the assumption that the biotin had 77 biotin molecules/dextran. 
Streptavidin (New England Biolabs) was added to achieve a 3:1:1 Env to streptavidin to 
biotin ratio. To generate YU2 SOSIP.664, a gene encoding YU2 SOSIP.664 was constructed 
to include the ‘SOS’ substitutions (A501Cgp120, T605Cgp41), the ‘IP’ substitution 
(I559Pgp41); changing the gp120-gp41 cleavage site to 6R (REKR to RRRRRR), and 
introducing a stop codon after residue 664gp41 (HXB2 numbering) analogous to mutations 
introduced to generate BG505 SOSIP.664 as described (Sanders et al., 2013). YU2 SOSIP.
664, BG505 SOSIP.664 and B41 SOSIP.664 (referred to as YU2 SOSIP, BG505 SOSIP and 
B41 SOSIP) were produced and purified by the 2G12/SEC method as previously described 
(Chung et al., 2014; Pugach et al., 2015; Sanders et al., 2013). YU2 gp140-F CD4bs knock-
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out is a YU2 gp140-foldon (F) HIV-1 Env with A281T and D368K mutations and proteins 
were produced as previously described (Forsell et al., 2008).
ELISA
ELISA for eOD-GT8, eOD-GT8 CD4bs knock-out, YU2 gp140-F, YU2 gp140-F knock-out, 
YU2 SOSIP and B41 SOSIP was performed by coating high binding 96-well plates 
(Corning Incorporated) with 200 ng/well of protein. After incubation overnight (ON) at 4 °C 
the plates were washed in wash buffer (PBS with 0.05% TWEEN 20 (Sigma)) and incubated 
in blocking buffer (PBS with 2% milk). Serum samples or monoclonal antibodies were 
added in dilutions. Plates were washed and secondary antibody, HRP conjugated anti-mouse 
or anti-human IgG (Jackson Immuno Research), was added. Plates were developed by the 
addition of HRP substrate (Life Technologies) and the absorbance was measured at 405 nm. 
ELISA specific for BG505 SOSIP was performed using the D7324-capture ELISA as 
described in (Sanders et al., 2013).
TZM-bl neutralization assay
Serum samples and monoclonal antibodies were tested for neutralization against a panel of 
selected HIV-1 pseudoviruses using a TZM-bl neutralization assay as previously described 
(Li et al., 2005).
B cell enrichment
B cells were enriched from single cell suspensions of total splenocytes prior to flow 
cytometry staining by magnetic bead separation using anti-CD19 or anti-CD43 MicroBeads 
(Miltenyi Biotec). The separation was performed on MACS separation LS columns 
according to the manufacturers instructions.
Flow Cytometry
Single cell suspensions of total splenocytes, enriched B cells or BM were stained with 
different combinations of the following antibodies: Anti-CD4 APC-eFluor 780, anti-CD8 
APC-eFluor 780, anti-Gr1 APC-eFluor 780, anti-F4/80 APC-eFluor 780, anti-B220 APC, 
anti-B220 APC-eFlour 780, anti-B220 FITC, anti CD19 PeCy7, anti-CD38 Alexa Fluor 700, 
anti-CD93 APC, anti-IgM PerCP-eFluor 710, anti CD21/CD35 eFluor 450 (eBiosciences), 
anti-CD23 PE (BioLegend), anti-CD4 PE-CF594, anti-CD8 PE-CF594, anti-Ly-6G and 
Ly-6C PE-CF594 and anti-IgG1 BV421 (BD biosciences). Live dead aqua stain was added 
to separate dead cells (Life Technologies) and eOD-GT8-specific cells were visualized by 
the addition of FITC-conjugated eOD-GT8 and PE-conjugated eOD-GT8 CD4bs knock-out. 
BG505 SOSIP- (Sok et al., 2014) and 2cc-specific memory B cells were visualized by the 
addition of biotinylated protein with the addition of streptavidin conjugated PE and APC 
respectively (BD Biosicences).
Single B cell sorting
Staining and single-cell sorting of naïve and memory B cells was performed as follows, for 
naïve mice CD4−, CD8−, Gr-1−, F4/80−, B220+ and IgM+ B cells were sorted. For 
immunized mice CD4−, CD8−, Gr-1−, F4/80−, B220+, CD38−, IgM−, IgG+, eOD-GT8 
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CD4bs knock-out- and eOD-GT8+ or CD4−, CD8−, Gr-1−, F4/80−, B220+, CD38−, IgM−, 
IgG+, BG505 SOSIP+ and 2cc+ memory B cells were single cell sorted into 96-well plates 
using a FACSAria III sorter (Becton Dickinson). The cells were lysed with 4 μl lysis buffer 
containing RNASin (Promega) 40 U/μl (0,3 μl), DPBS (Dulbecco) 10 x (0.2 μl), DTT 
(Invitrogen) 100 mM (0.4 μl) and nuclease-free water (3.1 μl). The sorted plates were stored 
at −80 °C until further processing (Tiller et al., 2009). Sequencing and cloning primers are 
listed in Table S6. Antibodies were cloned using a modified sequence and ligation-
independent cloning (SLIC) approach as described in (Li and Elledge, 2007). Antibodies 
were produced in HEK 293-6E cells as previously described (Klein et al., 2014).
Structural modeling
To create a structural model of one of the antibodies elicited in the MuVH mouse by BG505 
SOSIP, we integrated information from HIV bNAb structures and mouse light chain 
structures. The antibody 3BNC117 has very high sequence similarity to 3BNC60 (10 
mutations in heavy chain and 3 mutations in light chain (Scheid et al., 2011) and has a co-
crystal structure available (PDB id: 4JPV). We made an initial model of 3BNC60 by running 
50 ROSETTA-Fixbb (Leaver-Fay et al., 2011) simulations to model the mutations from the 
3BNC117 structure. The elicited antibodies contain a mutated mouse light chain from the 
VL10-94*01 germline gene, here we focused on the Q90H mutation. To model the light 
chain, we used an unrelated crystal structure of a mouse VL10-94*01 antibody (PDB id: 
1EMT). We superimposed the mouse antibody to the 3BNC60 model and created a hybrid 
of 3BNC60-mature heavy chain and VL10-94*01 light chain to mimic what was elicited in 
MuVH. The 1EMT structure did not contain a 5 amino acid CDRL3, so we aligned the light 
chain from 3BNC117 and grafted the 5 amino CDRL3 onto our model. The final model was 
obtained by adding an interfacial water molecule (as found in the structurally similar VRC-
CH31 light chain, PDB id: 4LSP) and by running 100 ROSETTA-Relax simulations to 
allow for slight movements of the backbone.
Statistical analysis
Statistical differences were analysed by the Mann-Whitney test. GraphPad Prism software 
was used for analysis and data were considered significant at * for p≤0.05, ** for p≤0.01 
and *** for p≤0.001.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. Characterization of B cells in GLVH and MuVH mice
(A) Representative FACS plots show binding of eOD-GT8 and eOD-GT8 CD4bs knock-out 
(KO) proteins by mature naive B cells in naive wild type C57Bl6 (WT), GLVH and MuVH 
mice. (B) Graph shows frequency of eOD-GT8-binding B cells in naive WT, GLVH and 
MuVH mice. Each dot represents one mouse. (C) Pie charts show heavy (HC) and light 
chain (LC) sequences cloned from purified single cell sorted naive B cells from naive mice. 
The number in the center of the pie chart is the number of sequences analyzed, each colored 
slice represents one clone (identical V gene and CDRL3) and its size is proportional to the 
size of the clone. White indicates unique sequences. (D) CDRL3 amino acid (aa) lengths 
from LCs in C. See also Figure S1.
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Figure 2. Antibody responses to immunization by GLVH mice
(A) Graphs show ELISA results of serum (1/900 dilution) for individual mice against eOD-
GT8 (blue) and eOD-GT8 CD4bs knock-out (KO, red) from wild type C57Bl6 (WT) and 
GLVH mice. Naive serum (0) and serum after one, two or three (1, 2 or 3) immunizations 
with eOD-GT8 60mers. (B) Graphs show ELISA results of serum (1/900 dilution) for 
individual mice against 426c.TM4ΔV1-3 (blue) or 426c.TM4ΔV1-3 CD4bs knock-out (KO, 
red) from wild type C57Bl6 (WT) and GLVH mice. Naive serum (0) and serum after one (1) 
immunization with multimerized 426c.TM4ΔV1-3. (C) Graphs show ELISA results of 
serum (1/300 dilution) for individual mice against BG505 SOSIP and YU2gp140-F in naive 
mice (0) or after three immunizations (3) with eOD-GT8 60mers. (D) Heavy (HC) and light 
chain (LC) sequences from single antigen binding B cells isolated from four eOD-GT8 
60mer-immunized GLVH mice. Pie charts as in Figure 1A. A clone is defined by identical V 
gene and similar CDRL3. (E) CDRL3 amino acid (aa) lengths from LCs in (D). (F) Graph 
shows ELISA results for monoclonal antibodies (5μg/ml) cloned from eOD-GT8 60mer-
immunized GLVH mice against eOD-GT8 (blue) and eOD-GT8 CD4bs knock-out (KO, 
red). (G) Graphs show ELISA results of serum (1/300 dilution) for individual mice against 
BG505 SOSIP or YU2 SOSIP in wild type C57Bl6 (WT) and GLVH mice after 
immunization with BG505 SOSIP or YU2 SOSIP respectively. Naive serum (0) and serum 
after two-(2) or three (3) immunizations. See also Figure S2, Figure S3 and Table S1.
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Figure 3. Antibody responses to immunization by MuVH mice
(A) Graphs show ELISA results of serum (1/300 dilution) for individual mice against eOD-
GT8 (blue) and eOD-GT8 CD4bs knock-out (KO, red), 2cc core and YU2 gp140-F. Naive 
serum (0) and serum after three (3) immunizations with eOD-GT8 60mer. (B) As in (A) but 
after BG505 SOSIP-immunization. ELISA against BG505 SOSIP, 2cc core and YU2 gp140-
F (blue) and YU2 gp140-F CD4bs knock-out (KO, red). (C) Neutralizing activity in TZM-bl 
assays of serum from individual naive, eOD-GT8 60mer- or BG505 SOSIP -immunized 
mice (M) against a panel of HIV-1 viruses. Numbers indicate the reciprocal dilution of 
serum at the median inhibitory concentration (IC50): red, >1000; orange, 100–1000; yellow, 
50–100 and white, was not neutralized at any dilution tested. Grey indicates background 
activities against the control MuLV virus. See also Figure S4.
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Figure 4. Monoclonal antibodies from immunized MuVH mice
(A) Pie charts show heavy (HC) and light (LC) sequences cloned from two eODGT8 60mer-
immunized (M#7 and 9) and three BG505 SOSIP-immunized (M#16, 17 and 18) MuVH 
mice. VL gene usage and CDRL3 sequences are shown for each clone, colors correspond to 
colors in pie charts. The same color indicate clones shared by different mice. A clone is 
defined by identical V gene and similar CDRL3. (B) CDRL3 amino acid (aa) lengths of the 
LCs in (A). (C) Graphs show ELISA results for individual monoclonal antibodies with the 
indicated CDRL3s cloned from eOD-GT8 60mer-immunized MuVH mice against eOD-GT8 
(blue) and eOD-GT8 CD4bs knock-out (KO, red) (at 0.55 μg/ml) or against YU2 gp140-F 
(at 5 μg/ml). (D) Neutralizing activity of a set of representative eOD-GT8 60mer- or BG505 
SOSIP- elicited monoclonal antibodies (mAbs) against 7 HIV-1 tier-2 viruses (1=MuLV 
control, 2=BG505/T 332N, 3=T247-23, 4=62357.14.D3.3489, 5=Q842.d12, 
6=3365.V2.c30, 7=YU2.DG, 8=0815.v3.c3) compared to the serum of the mouse they were 
cloned from. Colors for mAbs indicate concentration of mAb at the median inhibitory 
concentration (IC50): orange, 0.1 to 1 μg/ml; yellow, 1 to 10 μg/ml; green, 10–25 or 50 
μg/ml and white, not neutralized at any concentration tested. Lowest dilution tested for 
serum was 1:50, highest concentration tested for mAbs were between 10–50 μg/ml (see 
Table S3 and S5). X indicates sample not tested. The numbering of the antibodies 
corresponds to the numbering of the antibodies in Table S3 and S5. Colors and numbering 
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for serum as in Figure 3C. (E) Graphs show ELISA results for individual mAbs with the 
indicated CDRL3s cloned from BG505 SOSIP-immunized MuVH mice against eOD-GT8 
(blue) and eOD-GT8 CD4bs knock-out (KO, red) (at 0.55 μg/ml) or against YU2 gp140-F 
(at 5 μg/ml). See also Figure S4 and Table S2, S3, S4 and S5.
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Figure 5. Somatic mutations in immunized mice
(A) Graph shows number of light chain (LC) somatic hypermutations in individual 
sequences obtained after eOD-GT8 60mer- or BG505 SOSIP immunization in GLVH or 
MuVH mice. (B) LC somatic hypermutations in VL10-94*01 in individual sequences 
obtained after eOD-GT8 60mer- or BG505 SOSIP immunization in MuVH mice. (C) 
VL10-94*01 germline (GL) and 17 monoclonal antibodies (mAbs) from immunized MuVH 
mice sorted by neutralization strength. Neutralization data for each antibody tested against 
virus 1=T247-23, 2=62357.14.D3.3489, 3=BG505/T332N, 4=3365.v2.c30, 5=YU2.DG, 
6=0815.v3.c3, 7=HxBC2.DG and 8=MuLV. Colors for mAbs indicate concentration of 
mAb at the median inhibitory concentration (IC50): red, <0.1 μg/ml; orange, 0.1 to 1 μg/ml; 
yellow, 1 to 10 μg/ml; green, 10–25 or 50 μg/ml and white, not neutralized at any 
concentration tested (see also Table S3 and 5). Position of amino acid mutations in the LCs 
compared to germline are highlighted in red. X indicates sample not tested. (D) Graph 
shows neutralization score for VL10-94*01 cloned antibodies with Q90Q or Q90H CDRL3 
from immunized MuVH mice. Neutralization score: sum of viruses tested IC50 0.1–1 μg/ml: 
3, 1–10 μg/ml: 2, 10–50 μg/ml: 1 and >50 μg/ml: 0. (E) Somatic hypermutations in 
individual heavy chain sequences obtained after eOD-GT8 60mer- or BG505 SOSIP-
immunization in GLVH or MuVH mice. Data in (A), (B) and (E) are pooled from 9 mice 
(M#1, 2, 3, 4, 7, 9, 16, 17 and 18). (F) Somatic hypermutations in individual germinal center 
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B cell heavy chain (HC) sequences obtained from naive GLVH or MuVH mice. (G) Somatic 
hypermutations in individual germinal center B cell JH4 intron sequences obtained from 
naive GLVH or MuVH mice. Data in (F) and (G) are pooled from 2 independent experiments 
with 2–3 mice each. 80 clones were sequenced for GLVH or MuVH germinal center B cells 
HC and JH4. See also Figure S5, Table S3 and 5.
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